FMP
NASDAQ
199.92 USD
0.18 (0.09004%)
Mr. Mark C. McKenna
Healthcare
Biotechnology
https://www.prometheusbiosciences.com
NASDAQ
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated disea...
0001718852
US74349U1088
74349U108
9410 Carroll Park Drive
858 684 1300
US
97
Mar 12, 2021
0001718852
NASDAQ
Biotechnology
Healthcare
74349U108
US74349U1088
US
199.92
-0.49
1.22M
9.56B
-
23.27-199.96
52.09
-
-
-
-
-56.47
-
https://www.prometheusbiosciences.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.